Medical Director, Neurology Clinical Development

About Stoke

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine. Using Stoke’s proprietary approach, the company is developing antisense oligonucleotides (ASOs) to selectively restore naturally occurring protein levels. Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study.

Stoke entered into a strategic collaboration with Biogen in 2025 to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico;
Biogen receives exclusive rest of world commercialization rights.

STK-002 is Stoke’s proprietary antisense oligonucleotide (ASO) in clinical development for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. STK-002 has been granted orphan drug designation by the FDA. A Phase 1 study (OSPREY) of STK-002 in people with ADOA is now underway. The company is also conducting early research in Syngap1, a severe and rare neurodevelopmental disorder, in collaboration with Acadia Pharmaceuticals.

Stoke’s initial focus is on diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for the Company’s proprietary approach.

The Medical Director Neurology Clinical Development will play a key role in the planning, execution, and interpretation of clinical studies focused on transformative therapies for life‑threatening neurological diseases. This individual will contribute medical and scientific expertise to advance programs from early development through late‑stage studies and regulatory submission. The Medical Director will support cross‑functional teams, interface with external partners and investigators, and help ensure the highest standards of scientific and clinical rigor are maintained across all programs.

This role will report to the Senior Medical Director in Neurology Clinical Development.

• Support the design, implementation, and oversight of clinical trials in neurology, including protocol development, study conduct, and data analysis
• Contribute to the medical and scientific content of key clinical documents (e.g. protocols, investigator brochures, clinical study reports, and regulatory submissions)
• Participate in clinical data review, interpretation, and presentation to support timely and informed decision‑making
• Collaborate with safety/pharmacovigilance on safety review and signal evaluation
• Provide medical monitoring and clinical oversight for ongoing studies under the supervision of the Medical Director or Senior Medical Director
• Maintain effective collaboration with CROs, investigators, and academic partners to ensure study quality and adherence to timelines
• Ensure compliance with GCP, ICH, and all applicable regulatory and ethical guidelines

• Support the development of clinical development strategies and study designs in alignment with program objectives and scientific rationale
• Contribute to the development, execution, and continuous refinement of global Clinical Development Plans (CDPs)
• Integrate emerging data, literature, and competitive intelligence to inform ongoing program decisions and ensure scientific relevance and rigor
• Collaborate closely with cross‑functional partners including regulatory, clinical development operations, and biostatistics to ensure consistency and accuracy in study execution
• Participate in internal discussions and presentations to communicate key scientific insights, data interpretations, and development updates
• Contribute to the preparation and review of strategic and regulatory documents, including target product profiles, clinical sections of IND/CTA submissions, and briefing packages